<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Anticoagulation for the hemodialysis procedure
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Anticoagulation for the hemodialysis procedure
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Anticoagulation for the hemodialysis procedure
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Eugene C Kovalik, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Andrew Davenport, MD, FRCP
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Steve J Schwab, MD, FACP, FASN
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Eric N Taylor, MD, MSc, FASN
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Jan 30, 2024.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Hemodialysis (HD) and continuous kidney replacement therapies (CKRT) require blood access. Blood is exposed to surfaces of varying thrombogenicity as it travels through the HD and CKRT circuits. In the event of clotting in the blood circuit, approximately 180 to 200 mL of blood can be lost, due to an inability to return it back into the patient. In addition to loss of blood, clotting within the capillary fibers of the dialyzer results in reduced solute clearances and a shortened dialyzer lifespan. Thus, some form of anticoagulation (eg,
         <a class="drug drug_general" data-topicid="8518" href="/z/d/drug information/8518.html" rel="external">
          unfractionated heparin
         </a>
         [UFH]) is typically administered at the time of dialysis to prevent clotting in the blood circuit.
        </p>
        <p>
         This topic discusses anticoagulation for intermittent HD delivered in the setting of acute kidney injury or end-stage kidney disease. Anticoagulation for continuous therapies is discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/16855.html" rel="external">
          "Anticoagulation for continuous kidney replacement therapy"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3046322201">
         <span class="h1">
          ASSESSING BLEEDING RISK
         </span>
         <span class="headingEndMark">
          —
         </span>
         The use of anticoagulation for intermittent hemodialysis (HD) is common due to the propensity for clotting within the circuit. However, the decision to administer anticoagulation begins with assessment of a patient's bleeding risk.
        </p>
        <p>
         Patients who are on HD are generally prothrombotic, especially after a surgical procedure, and have an increased risk of clotting in the dialysis circuit. However, the risk of bleeding exceeds the risk of clotting in certain patient groups. These include patients with:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Severe thrombocytopenia (platelet count of &lt;20,000/microL)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Evidence of active bleeding from the gastrointestinal tract, intra-abdominal bleeding, extensive bleeding from surgical wounds, or from arterial or venous catheters at the time of dialysis
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Major surgery (especially intra-ocular and spinal surgeries) in the prior 72 hours  (
         <a class="graphic graphic_table graphicRef86929" href="/z/d/graphic/86929.html" rel="external">
          table 1
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Active intracranial or extradural hemorrhage
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Use of systemic anticoagulants
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Uremic pericarditis
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Coagulation factor VII or VIII deficiency
        </p>
        <p>
        </p>
        <p>
         Our approach to anticoagulation among these patients at high risk for bleeding is discussed below. (See
         <a class="local">
          'Patients at high risk for bleeding'
         </a>
         below.)
        </p>
        <p>
         Patients who do not have the above conditions are deemed standard risk and are treated with anticoagulation as below. (See
         <a class="local">
          'Standard-risk patients'
         </a>
         below.)
        </p>
        <p>
         Patients with deficiencies of clotting factors IX, XI, and XII are not considered high-risk for bleeding with anticoagulation during routine outpatient HD. This is because clotting of the hemodialysis circuit is primarily driven by factor VII, along with platelet and leukocyte activation. However, patients with hemophilia A (factor VIII deficiency) may have prolonged bleeding after needles are removed from the arteriovenous access site and may require administration of recombinant factor VIII prior to needle removal. Thus, deficiencies of clotting factors other than factor VII and VIII do not pose a higher risk for bleeding while the patients are on HD [
         <a href="#rid1">
          1-3
         </a>
         ].
        </p>
        <p>
         Use of antiplatelet agents alone is not considered a risk factor for bleeding among patients receiving HD. In addition, combinations of antiplatelet agents, such as
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         and
         <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">
          clopidogrel
         </a>
         at standard doses, do not appear to increase the risk of bleeding at needle sites; however, one study reported that higher dose combinations may increase needle-site bleeding in patients using arteriovenous grafts [
         <a href="#rid4">
          4
         </a>
         ].
        </p>
        <p>
         Patients who have undergone major surgery are often prothrombotic shortly after the procedure. Their risk of bleeding falls exponentially with time, leaving them at no higher risk of bleeding beyond 72 hours of surgery as compared with standard-risk patients [
         <a href="#rid5">
          5
         </a>
         ].
        </p>
        <p>
         Our approach to identifying patients at high risk of bleeding is largely based upon our clinical experience. A majority of the literature in this area comes from an era when larger doses (than what we now recommend) of
         <a class="drug drug_general" data-topicid="8518" href="/z/d/drug information/8518.html" rel="external">
          unfractionated heparin
         </a>
         (UFH) were used to mitigate the thrombogenic potential of older HD equipment (which is no longer in use). Over time, there have been major improvements in the biocompatibility of materials used in the extracorporeal circuit and in the manufacturing processes, leading to greater surface smoothness. These changes have helped lower the thrombogenic potential of the dialysis circuit. As a result, the doses of UFH used in clinical practice have declined substantially over time. Thus, literature reflective of the prior era practices may not be entirely applicable to decision-making pertaining to the prevailing use of UFH [
         <a href="#rid6">
          6-8
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2796466287">
         <span class="h1">
          OUR APPROACH
         </span>
        </p>
        <p class="headingAnchor" id="H1784915413">
         <span class="h2">
          Standard-risk patients
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with standard risk for anticoagulation constitute the majority of the dialysis population. The use of anticoagulation varies globally. Both
         <a class="drug drug_general" data-topicid="8518" href="/z/d/drug information/8518.html" rel="external">
          unfractionated heparin
         </a>
         (UFH) and low-molecular-weight heparin (LMWH) protocols are effective, have similar safety profiles, and are equally acceptable strategies [
         <a href="#rid9">
          9,10
         </a>
         ]. Thus, we use one of the following two approaches in standard-risk patients:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="8518" href="/z/d/drug information/8518.html" rel="external">
          Unfractionated heparin
         </a>
         <strong>
         </strong>
         – Dialysis units in many regions, including North America, use UFH for anticoagulation during hemodialysis (HD). We administer a bolus of 2000 units at the beginning of dialysis, followed by a continuous infusion of 500 units per hour. This infusion is usually turned off 60 minutes before the end of the dialysis session but can be adjusted depending upon an individual patient's clotting tendencies in the last hour of dialysis. If clotting develops, then we stop 30 minutes before the termination of dialysis. Many centers in Europe use an initial UFH bolus dose of 1000 units rather than 2000 units.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         An alternative approach is to customize the dose of the bolus to the patient's weight. With this approach, a bolus of 500 IU is administered for adult patients weighing &lt;50 kg, 1000 IU for patients weighing between 50 and 100 kg, and 2000 IU for patients weighing &gt;100 kg.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Various other permutations of UFH anticoagulation have been used by some units, although they may increase the burden on dialysis nursing staff, which may increase the chances of dosing errors, and therefore are less preferred. They include giving a bolus without a continuous infusion; a continuous infusion without a bolus; an initial bolus with a second mid-treatment bolus but without a continuous infusion; and an initial bolus followed by a declining infusion rate for the continuous infusion.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Low-molecular-weight heparins
         </strong>
         – LMWH use for anticoagulation during HD predominates in Western Europe, parts of Asia, and Australia. Dosing of LMWHs depends upon the drug used, due to their varying half-lives, and upon the length of the dialysis session. As an example,
         <a class="drug drug_general" data-topicid="10009" href="/z/d/drug information/10009.html" rel="external">
          tinzaparin
         </a>
         (LMWH with the shortest half-life) is typically dosed as a bolus of 2500 anti-Xa units for a four-hour dialysis session, whereas
         <a class="drug drug_general" data-topicid="9407" href="/z/d/drug information/9407.html" rel="external">
          enoxaparin
         </a>
         (LMWH with the longest half-life) is typically dosed at 20 mg for a four-hour dialysis session. Patients treated with a short-acting LMWH like tinzaparin may also need a second bolus for sessions longer than four hours (either the same dose or smaller dose depending upon the time remaining on dialysis), though some centers report that a single bolus provides adequate circuit anticoagulation for dialysis sessions lasting up to eight hours [
         <a href="#rid11">
          11
         </a>
         ]. We administer LMWH in the arterial limb of the dialyzer, which may lead to some loss of drug in the dialyzer [
         <a href="#rid12">
          12
         </a>
         ]. This loss can be minimized by administering the LMWH bolus after the patient has been on dialysis for approximately two to three minutes [
         <a href="#rid13">
          13
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Alterations to this standard prescription may be needed if bleeding or clotting are encountered during an HD session:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         If there is clotting detected in the venous air chamber and dialyzer header in the first half of the dialysis session, then we increase the UFH bolus in 500 IU increments per treatment, for a maximum of 4000 units.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         If clotting is detected in the second half of the session, then we increase the UFH infusion rate by 100 IU/hour every treatment to a maximum of 1000 IU/hour.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Patients who have clotting while being treated with LMWH have their bolus increased sequentially over the subsequent dialysis sessions.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Usually, the first of these changes to the dose of UFH or LMWH for clotting are made during the patient's next dialysis treatment.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         If recurrent filter clotting continues to remain a problem despite appropriate titration of anticoagulants, then we evaluate the patient for a dialysis access inflow or outflow stenosis.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         If bleeding from needle sites at the end of the HD session takes longer than seven minutes to stop, then we lengthen the time between cessation of the UFH infusion and end of dialysis (typically 60 minutes) in 10-minute increments until the time required for the bleeding to stop is seven minutes or under. For patients on LMWH who have prolonged bleeding from their access, we lower the bolus dose for the following dialysis session. All patients with persistent prolonged access bleeding should also undergo evaluation of their HD access. (See
         <a class="medical medical_review" href="/z/d/html/112108.html" rel="external">
          "Overview of hemodialysis arteriovenous fistula maintenance and thrombosis prevention", section on 'Venous stenotic lesions'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/112108.html" rel="external">
          "Overview of hemodialysis arteriovenous fistula maintenance and thrombosis prevention", section on 'Thrombosis without identified stenotic lesion'
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         Patients on HD are at greater risk of developing atrial fibrillation and stroke. As such, an increasing number of patients are treated with oral anticoagulants, including vitamin K antagonists (
         <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">
          warfarin
         </a>
         ), anti-Xa antagonists (
         <a class="drug drug_general" data-topicid="85642" href="/z/d/drug information/85642.html" rel="external">
          apixaban
         </a>
         ), and, more recently, anti-X1 monoclonals (osocimab/xisomab) [
         <a href="#rid14">
          14
         </a>
         ]. Patients prescribed warfarin anticoagulation for artificial metallic heart valves with an international normalized ratio target of 3.5 to 4.5 generally do not require additional anticoagulation for HD, whereas those anticoagulated for atrial fibrillation often require anticoagulation. However, the dose of systemic anticoagulant chosen should be minimized by reducing loading doses for UFH and LMWHs.
        </p>
        <p>
         Our approach requires minimal staff intervention and is standard in most HD units [
         <a href="#rid15">
          15,16
         </a>
         ]. In addition, our approach allows for individual modifications based upon issues encountered, and for variable heparin pharmacokinetics in a given patient.
        </p>
        <p class="headingAnchor" id="H4144595029">
         <span class="h2">
          Patients at high risk for bleeding
         </span>
         <span class="headingEndMark">
          —
         </span>
         There is no standard practice to prevent clotting of the HD circuit among patients who are at high risk for bleeding. Protocols differ across institutions and countries. Two approaches used at our institutions are outlined below:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          No-heparin method
         </strong>
         – With this method, the circuit is primed with isotonic
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          saline
         </a>
         alone, prior to a patient's arrival. Then, while the patient is on HD, the arterial (predialyzer) limb of the circuit is flushed with 200 mL of isotonic saline every hour for the duration of the HD session  (
         <a class="graphic graphic_figure graphicRef56596" href="/z/d/graphic/56596.html" rel="external">
          figure 1
         </a>
         ) [
         <a href="#rid17">
          17-20
         </a>
         ]. This additional saline flushed is factored into the ultrafiltration goals for the treatment session in order to minimize hypervolemia. Nurses caring for such patients need to be vigilant for any arterial and venous pressure alarms, and for observing for any visible clots in the dialyzer and bubble traps. (See
         <a class="medical medical_review" href="/z/d/html/1887.html" rel="external">
          "Overview of the hemodialysis apparatus", section on 'Dialyzers'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1887.html" rel="external">
          "Overview of the hemodialysis apparatus", section on 'Dialysis tubing'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         This approach of hourly
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          saline
         </a>
         flushes minimizes hemoconcentration and washes fibrin strands from the dialyzer into the bubble trap. A major disadvantage of this method is the need for closer staff supervision of the patient, and additional ultrafiltration is required to achieve adequate sodium removal.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Heparinized solution rinse or heparin-bonded dialyzer
         </strong>
         – A heparinized
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          saline
         </a>
         solution, made by adding 10,000 to 20,000 units of UFH in 1000 to 2000 mL of isotonic saline, is flushed through the hemodialysis circuit prior to the patient's arrival. Then, this unfractionated heparinized solution is rinsed out with isotonic saline prior to connecting the patient to the HD circuit. Binding of heparin to the dialyzer depends upon surface composition and charge. Heparin-bonded dialyzers are also commercially available, though these dialyzers have not been shown to have an advantage compared with other anticoagulant-free regimens [
         <a href="#rid21">
          21
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Whether or not using a heparinized solution rinse or heparin-bonded dialyzer is superior to the no-heparin method is unclear [
         <a href="#rid22">
          22-24
         </a>
         ]. One trial found more shortened treatments, more membrane clotting, and greater thrombin generation with the use of heparin-bonded dialyzers with citrate-containing dialysate and no systemic anticoagulation compared with use of heparin-bonded dialyzers with systemic heparin [
         <a href="#rid25">
          25
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Predilution hemodiafiltration
         </strong>
         –
         <strong>
         </strong>
         Hemodiafiltration is an option in some countries, and predilution hemodiafiltration has similarities to the constant
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          saline
         </a>
         infusion technique. Studies have reported a greater than 90 percent treatment success when combining predilution hemodiafiltration with citrate-containing dialysate [
         <a href="#rid26">
          26
         </a>
         ]. However, this may be dependent on dialyzer hemocompatibility [
         <a href="#rid27">
          27
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Most patients at high risk of bleeding are switched to a heparin-based protocol once their risk of bleeding is mitigated (eg, several days of stabilization after bleeding events or procedures). (See
         <a class="local">
          'Standard-risk patients'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2768103151">
         <span class="h2">
          Patients with recurrent filter thrombosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with standard risk for bleeding who have recurrent filter thrombosis should have the dose of UFH or LMWH adjusted as discussed above. (See
         <a class="local">
          'Standard-risk patients'
         </a>
         above.)
        </p>
        <p>
         Patients with a high risk for bleeding who are treated with the no-heparin method and who have recurrent filter thrombosis can have the following interventions undertaken, depending upon local feasibility:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Increase the blood flow rate and the needle gauge, if not already maximized. In countries where daily hemodiafiltration (HDF) is available, converting to short daily HDF with a high volume of predilutional (upstream) infusate (ie, &gt;40 L) may be a reasonable option. Details of HDF are discussed at length elsewhere [
         <a href="#rid28">
          28,29
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/94765.html" rel="external">
          "Technical aspects of hemodiafiltration"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         More frequent
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          saline
         </a>
         flushes (eg, every 30 minutes instead of every hour) as used in the "no-heparin method" among patients at high risk for bleeding. (See
         <a class="local">
          'Patients at high risk for bleeding'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p>
         Patients who fail these interventions and continue to have recurrent thrombosis can be transitioned to heparin-based anticoagulation (beginning at a lower dose), or be treated with either citrate dialysate or daily high-volume HDF combined with
         <a class="drug drug_general" data-topicid="9411" href="/z/d/drug information/9411.html" rel="external">
          epoprostenol
         </a>
         regional anticoagulation:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Heparin-based anticoagulation
         </strong>
         – If the patient is transitioned to heparin-based anticoagulation, we treat with a 1000 unit bolus of UFH at the beginning of dialysis (sometimes referred to as "tight-heparin"). If clotting continues, we use a 1000 unit UFH bolus at the beginning of dialysis followed by an infusion at 500 units/hour, turned off in the last 60 minutes of dialysis (sometimes referred to as "mini-heparin"). If needed, the standard approach described above can be used (see
         <a class="local">
          'Standard-risk patients'
         </a>
         above). For patients treated with LMWH, we treat with lower doses.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Citrate dialysate
         </strong>
         – Citric acid can be used as a partial or total replacement of acetate or bicarbonate in the dialysate [
         <a href="#rid30">
          30,31
         </a>
         ]. Citrate dialysate results in reduced clotting compared with no-heparin dialysis (by binding to ionized calcium, thereby interfering with the clotting cascade). The major safety concern with citrate dialysate is the potential for a decrease in ionized calcium and magnesium. At a citric acid concentration of 2.4 mEq/L, a small change in serum calcium and magnesium does occur, although usually not enough to cause symptoms [
         <a href="#rid32">
          32
         </a>
         ]. Citrate dialysate is generally only used in a hospital-based dialysis unit where calcium and magnesium can be monitored.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          High-volume HDF with
         </strong>
         <a class="drug drug_general" data-topicid="9411" href="/z/d/drug information/9411.html" rel="external">
          epoprostenol
         </a>
         <strong>
         </strong>
         – The arachidonic metabolite epoprostenol is a vasodilator and inhibitor of platelet aggregation. The in-vitro half-life of epoprostenol is three to five minutes, due to rapid metabolism by endothelial smooth muscle. Epoprostenol regional anticoagulation involves the infusion of epoprostenol into the arterial limb of the dialyzer circuit at 4 to 8 ng/kg/minute [
         <a href="#rid33">
          33,34
         </a>
         ]. Side effects include headache, lightheadedness, and facial flushing, largely resulting from vasodilation and hypotension. To avoid hypotension, the epoprostenol infusion is started at 0.5 ng/kg/min and then increased in a step-wise manner by doubling the infusion rate every two minutes up to a maximum rate of 8 ng/kg/min. Due to its short half-life, epoprostenol is metabolized by the time it enters the systemic circulation, thereby acting as a regional anticoagulant. The technique of short daily high-volume HDF is discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/94765.html" rel="external">
          "Technical aspects of hemodiafiltration"
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         If a patient continues to have recurrent thrombosis despite dose modifications to their anticoagulation regimen and having their dialysis access evaluated, then we pursue a hematological evaluation to look for prothrombotic tendencies. This often involves consultation with a hematologist to interpret results of such testing and to formulate a management plan. Such evaluation for prothrombotic tendencies should include conditions such as thrombocythemia, increased factor VIII, prothrombin mutations, factor V Leiden, anticardiolipin antibodies, antibodies to platelet factor 4 (PF4), and reduced natural anticoagulants (antithrombin and proteins S and C).
        </p>
        <p class="headingAnchor" id="H3620005313">
         <span class="h2">
          Patients with heparin-induced thrombocytopenia
         </span>
         <span class="headingEndMark">
          —
         </span>
         There are two forms of heparin-induced thrombocytopenia (HIT), only one of which is clinically significant (type 2):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          HIT type I
         </strong>
         is a mild, transient, and self-limited drop in platelet count that typically occurs within the first two days of UFH exposure. It appears to result from nonimmune platelet aggregation by a direct effect on platelets. No change in dialysis-related anticoagulation management is warranted for HIT type 1. (See
         <a class="medical medical_review" href="/z/d/html/90261.html" rel="external">
          "Clinical presentation and diagnosis of heparin-induced thrombocytopenia", section on 'Terminology and HIT variants'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          HIT type II
         </strong>
         is a clinically significant condition resulting from antibodies to PF4 complexed to UFH, referred to as "HIT antibodies" or "PF4/heparin antibodies." These antibodies can cause thrombosis and thrombocytopenia. Suspected or confirmed HIT type 2 warrants anticoagulation using a nonheparin strategy. A diagnosis of HIT type II should be noted in patients' charts to prevent inadvertent instillation of a heparin lock at the end of a dialysis session. The treatment is often guided by a hematologist and is presented elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/90261.html" rel="external">
          "Clinical presentation and diagnosis of heparin-induced thrombocytopenia", section on 'Terminology and HIT variants'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/90261.html" rel="external">
          "Clinical presentation and diagnosis of heparin-induced thrombocytopenia", section on 'Pathophysiology'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1369.html" rel="external">
          "Management of heparin-induced thrombocytopenia"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H112715386">
         <span class="h1">
          SPECIAL CONSIDERATIONS FOR INPATIENT HEMODIALYSIS
         </span>
        </p>
        <p class="headingAnchor" id="H998156687">
         <span class="h2">
          Inpatients with acute kidney injury requiring hemodialysis
         </span>
         <span class="headingEndMark">
          —
         </span>
         We typically use the "no-heparin method" among inpatients who receive hemodialysis (HD) for acute kidney injury. If such patients have recurrent filter clotting, then we use the same
         <a class="drug drug_general" data-topicid="8518" href="/z/d/drug information/8518.html" rel="external">
          unfractionated heparin
         </a>
         (UFH) or low-molecular-weight heparin (LMWH) protocol as for standard-risk patients. (See
         <a class="local">
          'Standard-risk patients'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H584887435">
         <span class="h2">
          Inpatients who are on chronic hemodialysis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Among patients who are on chronic HD for end-stage kidney disease, we mimic the patient's outpatient anticoagulation regimen while they are admitted. The only exception to this is if a patient is admitted for evaluation and management of a bleeding event or about to undergo a major procedure. We assess their risk for bleeding during the admission as outlined above. (See
         <a class="local">
          'Assessing bleeding risk'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H3018565760">
         <span class="h1">
          METHODS SELDOM USED
         </span>
        </p>
        <p>
         Methods seldom used for anticoagulation during dialysis include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="115978" href="/z/d/drug information/115978.html" rel="external">
          Regional citrate anticoagulation
         </a>
         – The regional citrate regimen involves the continuous infusion of isosmotic trisodium citrate solution (102 mmol/L) into the arterial limb of the dialyzer  (
         <a class="graphic graphic_figure graphicRef67592" href="/z/d/graphic/67592.html" rel="external">
          figure 2
         </a>
         ) [
         <a href="#rid35">
          35,36
         </a>
         ]. The anticoagulant activity of this regimen results from binding of citrate to calcium, which interrupts the coagulation cascade. Most centers use a calcium-free dialysate, and regional citrate anticoagulation can be used for low- and high-flux hemodialysis and hemodiafiltration [
         <a href="#rid37">
          37
         </a>
         ]. Centers differ in the citrate concentration entering the dialyzer (2.7 to 4 mmol/L), but higher concentrations have not been demonstrated to improve hemocompatibility [
         <a href="#rid38">
          38
         </a>
         ], and others have reported successful dialysis sessions when using calcium-free dialysate alone without citrate and calcium reinfusion [
         <a href="#rid39">
          39
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Citrate anticoagulation is reversed by the infusion of 5 percent
         <a class="drug drug_general" data-topicid="9186" href="/z/d/drug information/9186.html" rel="external">
          calcium chloride
         </a>
         into the venous return line at a rate of 0.5 mL/min. This rate is constantly adjusted according to frequent measurements of plasma calcium concentration to prevent hypocalcemia or hypercalcemia [
         <a href="#rid40">
          40
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Comparative trials have shown a reduced incidence of bleeding with these regimens when compared with standard UFH protocols [
         <a href="#rid41">
          41,42
         </a>
         ]. The major problem with
         <a class="drug drug_general" data-topicid="115978" href="/z/d/drug information/115978.html" rel="external">
          regional citrate anticoagulation
         </a>
         is hypocalcemia or hypercalcemia, hypernatremia (due to the hypertonic sodium citrate solution), and metabolic alkalosis (due to bicarbonate generated during the metabolism of citrate) that may require hydrochloric acid infusion. If closely monitored, however, the complication rate is relatively low [
         <a href="#rid40">
          40,42,43
         </a>
         ]. Specifically designed dialysate may also lower the incidence of electrolyte abnormalities, including metabolic alkalosis [
         <a href="#rid44">
          44
         </a>
         ]. The effectiveness of regional citrate anticoagulation varies between centers and may be affected by type of dialysis access, choice of dialyzer, the use of hemodiafiltration, and a variety of patient factors [
         <a href="#rid45">
          45
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Regional anticoagulation with nafamostat
         </strong>
         – Nafamostat is a serine protease inhibitor that does not have the hypotensive side effects of prostacyclin [
         <a href="#rid46">
          46
         </a>
         ]. It is mainly used as an alternative to citrate or prostacyclin in Japan, China, and South Korea. Nafamostat has a relatively short half-life of five to eight minutes and requires an initial bolus followed by an infusion, adjusted according to the activated partial thromboplastin time (aPTT). The main advantage of this drug is that no further titration is needed once goal aPTT is met, allowing for a tight control in patients at high risk of bleeding. It may, however, be associated with an unacceptably high incidence of clot formation. In one study using nafamostat, clot formation was observed in up to 36 percent of dialyzers despite adequate prolongation of the aPTT [
         <a href="#rid47">
          47
         </a>
         ]. In addition, nafamostat should not be used with polyacrylonitrile dialysis membranes due to adsorption onto the membrane surface. Nafamostat is very expensive outside of Japan and is not yet available in the United States.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1039003678">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/112932.html" rel="external">
          "Society guideline links: Dialysis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3683741">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          General principles
         </strong>
         – Hemodialysis (HD) and continuous kidney replacement therapies (CKRT) are typically delivered with some form of anticoagulation (eg,
         <a class="drug drug_general" data-topicid="8518" href="/z/d/drug information/8518.html" rel="external">
          unfractionated heparin
         </a>
         [UFH] or low-molecular-weight heparin [LMWH]) to prevent clotting in the blood circuit. (See
         <a class="local">
          'Introduction'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Assessing bleeding risk
         </strong>
         – Patients on chronic HD are generally prothrombotic. However, the risk of bleeding exceeds the risk of clotting among patients who have severe thrombocytopenia, evidence of active bleeding, a history of major surgery within the prior 72 hours  (
         <a class="graphic graphic_table graphicRef86929" href="/z/d/graphic/86929.html" rel="external">
          table 1
         </a>
         ), active intracranial or extradural hemorrhage, uremic pericarditis, coagulation factor VII or VIII deficiency, or who are being treated with systemic anticoagulants. Patients who are on antiplatelet agents alone are not considered to be at a high risk for bleeding. (See
         <a class="local">
          'Assessing bleeding risk'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Approach to anticoagulation
         </strong>
         – Our approach to anticoagulation depends upon an individualized assessment of a patient's risk of bleeding or thrombosis:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Standard-risk patients
         </strong>
         – We treat standard-risk patients (who are not at higher risk for bleeding or thrombosis) with either UFH or LMWH. Details of dosing options, administration, and alterations in dosing in the setting of bleeding or thrombosis are discussed above. (See
         <a class="local">
          'Standard-risk patients'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Patients at high risk for bleeding
         </strong>
         – Patients at high risk for bleeding are treated with the "no-heparin" method  (
         <a class="graphic graphic_figure graphicRef56596" href="/z/d/graphic/56596.html" rel="external">
          figure 1
         </a>
         ), heparinized solution rinse, or heparin-bonded dialyzer. Most patients at high risk of bleeding are switched to a heparin-based protocol once their risk of bleeding is mitigated (eg, several days of stabilization after bleeding events or procedures). (See
         <a class="local">
          'Patients at high risk for bleeding'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Patients with recurrent filter thrombosis
         </strong>
         – Patients at standard risk for bleeding who have recurrent filter thrombosis should have their UFH or LMWH increased. Patients at high risk for bleeding who have recurrent filter thrombosis should have their blood flow and needle gauge maximized and frequency of
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          saline
         </a>
         flushes increased. Those who continue to have recurrent filter thrombosis despite these interventions should either be transitioned to a UFH-based regimen, Citrasate (brand name) dialysate, or to hemodiafiltration with
         <a class="drug drug_general" data-topicid="9411" href="/z/d/drug information/9411.html" rel="external">
          epoprostenol
         </a>
         regional anticoagulation. Details of these methods are discussed above. (See
         <a class="local">
          'Patients with recurrent filter thrombosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Patients with heparin-induced thrombocytopenia (HIT)
         </strong>
         – Patients who have HIT type I do not require any changes in their anticoagulation regimen. Patients who have HIT type II should not be treated with any UFH or LMWH products and need to be comanaged for HIT in concert with hematologists. (See
         <a class="local">
          'Patients with heparin-induced thrombocytopenia'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/1369.html" rel="external">
          "Management of heparin-induced thrombocytopenia"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Inpatients with acute kidney injury (AKI)
         </strong>
         – Patients who are admitted to a hospital with AKI requiring HD are generally treated without anticoagulation, unless they have recurrent filter thrombosis, in which case they are treated with UFH or LMWH similar to standard-risk patients. (See
         <a class="local">
          'Inpatients with acute kidney injury requiring hemodialysis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Inpatients on chronic HD
         </strong>
         – Patients on chronic HD who are admitted to a hospital are continued on their outpatient anticoagulation regimen. The exception to this is made for patients who are admitted for evaluation of a bleeding event or for a major procedure, and such patients are treated without anticoagulation until their bleeding risk is mitigated. (See
         <a class="local">
          'Inpatients who are on chronic hemodialysis'
         </a>
         above.)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Frank RD, Mueller U, Lanzmich R, Floege J. Factor XII activation markers do not reflect FXII dependence of thrombin generation induced by polyvinylchloride. J Mater Sci Mater Med 2013; 24:2561.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Takamizawa Y, Araki M, Yoshida N, et al. A case of a severe factor XI deficiency in patient undergoing hemodialysis without the use of heparin. Blood Coagul Fibrinolysis 2014; 25:898.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shinoda BA, Mason RG. Reaction of blood with artificial surfaces of hemodialyzers. Studies of human blood with platelet defects or coagulation factor deficiencies. Biomater Med Devices Artif Organs 1978; 6:305.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kaufman JS, O'Connor TZ, Zhang JH, et al. Randomized controlled trial of clopidogrel plus aspirin to prevent hemodialysis access graft thrombosis. J Am Soc Nephrol 2003; 14:2313.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Douketis JD, Spyropoulos AC, Spencer FA, et al. Perioperative management of antithrombotic therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:e326S.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Swartz RD. Hemorrhage during high-risk hemodialysis using controlled heparinization. Nephron 1981; 28:65.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Goldsmith HJ. Haemorrhage in high-risk haemodialysis--low heparin dose. Nephron 1982; 31:96.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Biggers JA, Remmers AR Jr, Glassford DM, et al. The risk of anticoagulation in hemodialysis patients. Nephron 1977; 18:109.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lohr JW, Schwab SJ. Minimizing hemorrhagic complications in dialysis patients. J Am Soc Nephrol 1991; 2:961.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schrader J, Stibbe W, Kandt M, et al. Low molecular weight heparin versus standard heparin. A long-term study in hemodialysis and hemofiltration patients. ASAIO Trans 1990; 36:28.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Harvey B, Lafrance JP, Elftouh N, et al. Single-Bolus Tinzaparin Anticoagulation in Extended Hemodialysis Session: A Feasibility Study. Kidney360 2023; 4:641.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Polkinghorne KR, McMahon LP, Becker GJ. Pharmacokinetic studies of dalteparin (Fragmin), enoxaparin (Clexane), and danaparoid sodium (Orgaran) in stable chronic hemodialysis patients. Am J Kidney Dis 2002; 40:990.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dhondt A, Pauwels R, Devreese K, et al. Where and When To Inject Low Molecular Weight Heparin in Hemodiafiltration? A Cross Over Randomised Trial. PLoS One 2015; 10:e0128634.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Eikelboom J, Floege J, Thadhani R, et al. Anticoagulation in patients with kidney failure on dialysis: factor XI as a therapeutic target. Kidney Int 2021; 100:1199.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ouseph R, Brier ME, Ward RA. Improved dialyzer reuse after use of a population pharmacodynamic model to determine heparin doses. Am J Kidney Dis 2000; 35:89.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ouseph R, Ward RA. Anticoagulation for intermittent hemodialysis. Semin Dial 2000; 13:181.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sanders PW, Taylor H, Curtis JJ. Hemodialysis without anticoagulation. Am J Kidney Dis 1985; 5:32.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stamatiadis DN, Helioti H, Mansour M, et al. Hemodialysis for patients bleeding or at risk for bleeding, can be simple, safe and efficient. Clin Nephrol 2004; 62:29.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schwab SJ, Onorato JJ, Sharar LR, Dennis PA. Hemodialysis without anticoagulation. One-year prospective trial in hospitalized patients at risk for bleeding. Am J Med 1987; 83:405.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sahota S, Rodby R. Inpatient hemodialysis without anticoagulation in adults. Clin Kidney J 2014; 7:552.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vanommeslaeghe F, De Somer F, Josipovic I, et al. Evaluation with micro-CT of different anticoagulation strategies during hemodialysis in patients with thrombocytopenia: A randomized crossover study. Artif Organs 2019; 43:756.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee KB, Kim B, Lee YH, et al. Hemodialysis using heparin-bound Hemophan in patients at risk of bleeding. Nephron Clin Pract 2004; 97:c5.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Guéry B, Alberti C, Servais A, et al. Hemodialysis without systemic anticoagulation: a prospective randomized trial to evaluate 3 strategies in patients at risk of bleeding. PLoS One 2014; 9:e97187.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Laville M, Dorval M, Fort Ros J, et al. Results of the HepZero study comparing heparin-grafted membrane and standard care show that heparin-grafted dialyzer is safe and easy to use for heparin-free dialysis. Kidney Int 2014; 86:1260.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           François K, De Clerck D, Tonnelier A, et al. Dialyzer Performance During Hemodialysis Without Systemic Anticoagulation Using a Heparin-Grafted Dialyzer Combined With a Citrate-Enriched Dialysate: Results of the Randomized Crossover Noninferiority EvoCit Study. Am J Kidney Dis 2022; 79:79.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vandenbosch I, Dejongh S, Claes K, et al. Strategies for asymmetrical triacetate dialyser heparin-free effective haemodialysis: the SAFE study. Clin Kidney J 2021; 14:1901.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vanommeslaeghe F, Josipovic I, Boone M, et al. How biocompatible haemodialysers can conquer the need for systemic anticoagulation even in post-dilution haemodiafiltration: a cross-over study. Clin Kidney J 2021; 14:1752.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           de Pont AC, Bouman CS, Bakhtiari K, et al. Predilution versus postdilution during continuous venovenous hemofiltration: a comparison of circuit thrombogenesis. ASAIO J 2006; 52:416.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zimbudzi E. Intermittent saline flushes or continuous saline infusion: what works better when heparin-free dialysis is recommended? Int J Nephrol Renovasc Dis 2013; 6:65.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ahmad S, Callan R, Cole JJ, Blagg CR. Dialysate made from dry chemicals using citric acid increases dialysis dose. Am J Kidney Dis 2000; 35:493.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tu A, Ahmad S. Heparin-free hemodialysis with citrate-containing dialysate in intensive care patients. Dial Transplant 2000; 29:620.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Meijers B, Metalidis C, Vanhove T, et al. A noninferiority trial comparing a heparin-grafted membrane plus citrate-containing dialysate versus regional citrate anticoagulation: results of the CiTED study. Nephrol Dial Transplant 2017; 32:707.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Swartz RD, Flamenbaum W, Dubrow A, et al. Epoprostenol (PGI2, prostacyclin) during high-risk hemodialysis: preventing further bleeding complications. J Clin Pharmacol 1988; 28:818.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Caruana RJ, Smith MC, Clyne D, et al. Controlled study of heparin versus epoprostenol sodium (prostacyclin) as the sole anticoagulant for chronic hemodialysis. Blood Purif 1991; 9:296.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pinnick RV, Wiegmann TB, Diederich DA. Regional citrate anticoagulation for hemodialysis in the patient at high risk for bleeding. N Engl J Med 1983; 308:258.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           von Brecht JH, Flanigan MJ, Freeman RM, Lim VS. Regional anticoagulation: hemodialysis with hypertonic trisodium citrate. Am J Kidney Dis 1986; 8:196.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Goet E, Wentz B, Frank RD. Regional citrate anticoagulation protocol suitable for intermittent hemodialysis and post-dilution hemodiafiltration. Clin Nephrol 2021; 96:90.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Orsag A, Bozic-Mijovski M, Hudoklin S, et al. Biocompatibility Parameters with Standard and Increased Dose of Citrate in Hemodialysis-A Randomized Trial. J Clin Med 2021; 10.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Medrano C, Cointault O, Lavayssiere L, et al. Heparin-free regional anticoagulation of haemodialysis filters with calcium-free dialysate: is citrate mandatory? Clin Kidney J 2021; 14:2534.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Apsner R, Buchmayer H, Lang T, et al. Simplified citrate anticoagulation for high-flux hemodialysis. Am J Kidney Dis 2001; 38:979.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Janssen MJ, Huijgens PC, Bouman AA, et al. Citrate versus heparin anticoagulation in chronic haemodialysis patients. Nephrol Dial Transplant 1993; 8:1228.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Flanigan MJ, Von Brecht J, Freeman RM, Lim VS. Reducing the hemorrhagic complications of hemodialysis: a controlled comparison of low-dose heparin and citrate anticoagulation. Am J Kidney Dis 1987; 9:147.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Apsner R, Buchmayer H, Gruber D, Sunder-Plassmann G. Citrate for long-term hemodialysis: prospective study of 1,009 consecutive high-flux treatments in 59 patients. Am J Kidney Dis 2005; 45:557.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Morgera S, Haase M, Ruckert M, et al. Regional citrate anticoagulation in continuous hemodialysis--acid-base and electrolyte balance at an increased dose of dialysis. Nephron Clin Pract 2005; 101:c211.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hu Z, Xu J, Gong Y, et al. Non-anticoagulant factors affecting coagulation in the extracorporeal circulation circuit and the development of an individualized regional citrate anticoagulation protocol for hemodialysis: A real-world retrospective study. Int J Artif Organs 2023; 46:329.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ota K, Kawaguchi H, Takahashi K, Ito K. A new prostacyclin analogue - an anticoagulant applicable to hemodialysis. Trans Am Soc Artif Intern Organs 1983; 29:419.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Matsuo T, Kario K, Nakao K, et al. Anticoagulation with nafamostat mesilate, a synthetic protease inhibitor, in hemodialysis patients with a bleeding risk. Haemostasis 1993; 23:135.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 1840 Version 29.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23864336" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Factor XII activation markers do not reflect FXII dependence of thrombin generation induced by polyvinylchloride.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24914741" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : A case of a severe factor XI deficiency in patient undergoing hemodialysis without the use of heparin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/312115" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Reaction of blood with artificial surfaces of hemodialyzers. Studies of human blood with platelet defects or coagulation factor deficiencies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12937308" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Randomized controlled trial of clopidogrel plus aspirin to prevent hemodialysis access graft thrombosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22315266" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Perioperative management of antithrombotic therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7290274" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Hemorrhage during high-risk hemodialysis using controlled heparinization.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7110481" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Haemorrhage in high-risk haemodialysis--low heparin dose.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/854139" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : The risk of anticoagulation in hemodialysis patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1760540" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Minimizing hemorrhagic complications in dialysis patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2155017" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Low molecular weight heparin versus standard heparin. A long-term study in hemodialysis and hemofiltration patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36921585" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Single-Bolus Tinzaparin Anticoagulation in Extended Hemodialysis Session: A Feasibility Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12407644" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Pharmacokinetic studies of dalteparin (Fragmin), enoxaparin (Clexane), and danaparoid sodium (Orgaran) in stable chronic hemodialysis patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26076014" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Where and When To Inject Low Molecular Weight Heparin in Hemodiafiltration? A Cross Over Randomised Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34600964" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Anticoagulation in patients with kidney failure on dialysis: factor XI as a therapeutic target.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10620549" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Improved dialyzer reuse after use of a population pharmacodynamic model to determine heparin doses.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10833779" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Anticoagulation for intermittent hemodialysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3881017" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Hemodialysis without anticoagulation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15267010" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Hemodialysis for patients bleeding or at risk for bleeding, can be simple, safe and efficient.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3310620" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Hemodialysis without anticoagulation. One-year prospective trial in hospitalized patients at risk for bleeding.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25859371" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Inpatient hemodialysis without anticoagulation in adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30820962" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Evaluation with micro-CT of different anticoagulation strategies during hemodialysis in patients with thrombocytopenia: A randomized crossover study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15153761" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Hemodialysis using heparin-bound Hemophan in patients at risk of bleeding.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24825343" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Hemodialysis without systemic anticoagulation: a prospective randomized trial to evaluate 3 strategies in patients at risk of bleeding.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25007166" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Results of the HepZero study comparing heparin-grafted membrane and standard care show that heparin-grafted dialyzer is safe and easy to use for heparin-free dialysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33940113" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Dialyzer Performance During Hemodialysis Without Systemic Anticoagulation Using a Heparin-Grafted Dialyzer Combined With a Citrate-Enriched Dialysate: Results of the Randomized Crossover Noninferiority EvoCit Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34345413" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Strategies for asymmetrical triacetate dialyser heparin-free effective haemodialysis: the SAFE study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34548919" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : How biocompatible haemodialysers can conquer the need for systemic anticoagulation even in post-dilution haemodiafiltration: a cross-over study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16883122" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Predilution versus postdilution during continuous venovenous hemofiltration: a comparison of circuit thrombogenesis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23637548" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Intermittent saline flushes or continuous saline infusion: what works better when heparin-free dialysis is recommended?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10692276" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Dialysate made from dry chemicals using citric acid increases dialysis dose.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Heparin-free hemodialysis with citrate-containing dialysate in intensive care patients
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28407129" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : A noninferiority trial comparing a heparin-grafted membrane plus citrate-containing dialysate versus regional citrate anticoagulation: results of the CiTED study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3068260" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Epoprostenol (PGI2, prostacyclin) during high-risk hemodialysis: preventing further bleeding complications.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1819317" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Controlled study of heparin versus epoprostenol sodium (prostacyclin) as the sole anticoagulant for chronic hemodialysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6848936" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Regional citrate anticoagulation for hemodialysis in the patient at high risk for bleeding.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3752075" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Regional anticoagulation: hemodialysis with hypertonic trisodium citrate.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33749584" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Regional citrate anticoagulation protocol suitable for intermittent hemodialysis and post-dilution hemodiafiltration.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34279471" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Biocompatibility Parameters with Standard and Increased Dose of Citrate in Hemodialysis-A Randomized Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34950464" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Heparin-free regional anticoagulation of haemodialysis filters with calcium-free dialysate: is citrate mandatory?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11684550" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Simplified citrate anticoagulation for high-flux hemodialysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8302461" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Citrate versus heparin anticoagulation in chronic haemodialysis patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3548336" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Reducing the hemorrhagic complications of hemodialysis: a controlled comparison of low-dose heparin and citrate anticoagulation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15754278" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Citrate for long-term hemodialysis: prospective study of 1,009 consecutive high-flux treatments in 59 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16155399" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Regional citrate anticoagulation in continuous hemodialysis--acid-base and electrolyte balance at an increased dose of dialysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37278534" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Non-anticoagulant factors affecting coagulation in the extracorporeal circulation circuit and the development of an individualized regional citrate anticoagulation protocol for hemodialysis: A real-world retrospective study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6369729" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : A new prostacyclin analogue - an anticoagulant applicable to hemodialysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8276316" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Anticoagulation with nafamostat mesilate, a synthetic protease inhibitor, in hemodialysis patients with a bleeding risk.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
